Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.

Anna Morisco, Antonella Accardo, Diego Tesauro, Rosanna Palumbo, Ettore Benedetti, Giancarlo Morelli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

New liposomal aggregates, prepared by combining together, in a 90:10 molar ratio, two amphiphilic monomers, one containing two hydrocarbon chains in the hydrophobic region and the anionic DOTA chelating agent as hydrophilic moiety, and the other containing the same hydrophobic moiety and the CCK8 peptide, are described. The liposomal aggregates because of the presence of the specific moiety, constituted by the CCK8 peptide, which selectively recognizes CCK receptors on tumor cells are used as drug carriers with the aim to deliver into tumor cells the appropriate antitumor drug. The drug loading content and the releasing properties of the liposomal aggregates are studied by the use of the cytotoxic doxorubicin as drug model. The doxorubicin loading content determination reveals that above 95% of the total drug was uptaken with a corresponding drug/lipid w/w ratio of 0.134. The cellular uptake of the targeted liposomal doxorubicin with respect to the self-assembled, nonspecific, liposomal doxorubicin is evaluated using flow cytometry assays. The doxorubicin cell content for two types of cell systems, namely, A431 and HuVEC cells, for peptide derivatized liposomes was 70- and 8-fold higher, respectively, than for nontargeted liposomes, indicating that the bioactive CCK8 peptide is able to enhance the doxorubicin uptake into the carcinoma cells in vitro. The cytotoxicity effect of liposomal doxorubicin on A431 cells has been assessed by MTT assays: in presence of drug amounts ranged between 250 and 1000 ng/ml, incubation with peptide derivatized liposomes showed significantly lower cell survival compared with nontargeted liposomes.

Original languageEnglish
Pages (from-to)88-96
Number of pages9
JournalBiopolymers
Volume96
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Doxorubicin
Liposomes
Peptides
Tumors
Cells
Pharmaceutical Preparations
Neoplasms
Assays
Cholecystokinin Receptors
Drug Carriers
Flow cytometry
Cytotoxicity
Chelating Agents
Hydrocarbons
Chelation
Antineoplastic Agents
Lipids
Monomers
Cell Survival
Flow Cytometry

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Biomaterials
  • Organic Chemistry

Cite this

Morisco, A., Accardo, A., Tesauro, D., Palumbo, R., Benedetti, E., & Morelli, G. (2011). Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. Biopolymers, 96(1), 88-96. https://doi.org/10.1002/bip.21491

Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. / Morisco, Anna; Accardo, Antonella; Tesauro, Diego; Palumbo, Rosanna; Benedetti, Ettore; Morelli, Giancarlo.

In: Biopolymers, Vol. 96, No. 1, 2011, p. 88-96.

Research output: Contribution to journalArticle

Morisco, A, Accardo, A, Tesauro, D, Palumbo, R, Benedetti, E & Morelli, G 2011, 'Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.', Biopolymers, vol. 96, no. 1, pp. 88-96. https://doi.org/10.1002/bip.21491
Morisco, Anna ; Accardo, Antonella ; Tesauro, Diego ; Palumbo, Rosanna ; Benedetti, Ettore ; Morelli, Giancarlo. / Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. In: Biopolymers. 2011 ; Vol. 96, No. 1. pp. 88-96.
@article{66839fb2ecdf4da8b6afb416c9f5fd8a,
title = "Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.",
abstract = "New liposomal aggregates, prepared by combining together, in a 90:10 molar ratio, two amphiphilic monomers, one containing two hydrocarbon chains in the hydrophobic region and the anionic DOTA chelating agent as hydrophilic moiety, and the other containing the same hydrophobic moiety and the CCK8 peptide, are described. The liposomal aggregates because of the presence of the specific moiety, constituted by the CCK8 peptide, which selectively recognizes CCK receptors on tumor cells are used as drug carriers with the aim to deliver into tumor cells the appropriate antitumor drug. The drug loading content and the releasing properties of the liposomal aggregates are studied by the use of the cytotoxic doxorubicin as drug model. The doxorubicin loading content determination reveals that above 95{\%} of the total drug was uptaken with a corresponding drug/lipid w/w ratio of 0.134. The cellular uptake of the targeted liposomal doxorubicin with respect to the self-assembled, nonspecific, liposomal doxorubicin is evaluated using flow cytometry assays. The doxorubicin cell content for two types of cell systems, namely, A431 and HuVEC cells, for peptide derivatized liposomes was 70- and 8-fold higher, respectively, than for nontargeted liposomes, indicating that the bioactive CCK8 peptide is able to enhance the doxorubicin uptake into the carcinoma cells in vitro. The cytotoxicity effect of liposomal doxorubicin on A431 cells has been assessed by MTT assays: in presence of drug amounts ranged between 250 and 1000 ng/ml, incubation with peptide derivatized liposomes showed significantly lower cell survival compared with nontargeted liposomes.",
author = "Anna Morisco and Antonella Accardo and Diego Tesauro and Rosanna Palumbo and Ettore Benedetti and Giancarlo Morelli",
year = "2011",
doi = "10.1002/bip.21491",
language = "English",
volume = "96",
pages = "88--96",
journal = "Biopolymers",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.

AU - Morisco, Anna

AU - Accardo, Antonella

AU - Tesauro, Diego

AU - Palumbo, Rosanna

AU - Benedetti, Ettore

AU - Morelli, Giancarlo

PY - 2011

Y1 - 2011

N2 - New liposomal aggregates, prepared by combining together, in a 90:10 molar ratio, two amphiphilic monomers, one containing two hydrocarbon chains in the hydrophobic region and the anionic DOTA chelating agent as hydrophilic moiety, and the other containing the same hydrophobic moiety and the CCK8 peptide, are described. The liposomal aggregates because of the presence of the specific moiety, constituted by the CCK8 peptide, which selectively recognizes CCK receptors on tumor cells are used as drug carriers with the aim to deliver into tumor cells the appropriate antitumor drug. The drug loading content and the releasing properties of the liposomal aggregates are studied by the use of the cytotoxic doxorubicin as drug model. The doxorubicin loading content determination reveals that above 95% of the total drug was uptaken with a corresponding drug/lipid w/w ratio of 0.134. The cellular uptake of the targeted liposomal doxorubicin with respect to the self-assembled, nonspecific, liposomal doxorubicin is evaluated using flow cytometry assays. The doxorubicin cell content for two types of cell systems, namely, A431 and HuVEC cells, for peptide derivatized liposomes was 70- and 8-fold higher, respectively, than for nontargeted liposomes, indicating that the bioactive CCK8 peptide is able to enhance the doxorubicin uptake into the carcinoma cells in vitro. The cytotoxicity effect of liposomal doxorubicin on A431 cells has been assessed by MTT assays: in presence of drug amounts ranged between 250 and 1000 ng/ml, incubation with peptide derivatized liposomes showed significantly lower cell survival compared with nontargeted liposomes.

AB - New liposomal aggregates, prepared by combining together, in a 90:10 molar ratio, two amphiphilic monomers, one containing two hydrocarbon chains in the hydrophobic region and the anionic DOTA chelating agent as hydrophilic moiety, and the other containing the same hydrophobic moiety and the CCK8 peptide, are described. The liposomal aggregates because of the presence of the specific moiety, constituted by the CCK8 peptide, which selectively recognizes CCK receptors on tumor cells are used as drug carriers with the aim to deliver into tumor cells the appropriate antitumor drug. The drug loading content and the releasing properties of the liposomal aggregates are studied by the use of the cytotoxic doxorubicin as drug model. The doxorubicin loading content determination reveals that above 95% of the total drug was uptaken with a corresponding drug/lipid w/w ratio of 0.134. The cellular uptake of the targeted liposomal doxorubicin with respect to the self-assembled, nonspecific, liposomal doxorubicin is evaluated using flow cytometry assays. The doxorubicin cell content for two types of cell systems, namely, A431 and HuVEC cells, for peptide derivatized liposomes was 70- and 8-fold higher, respectively, than for nontargeted liposomes, indicating that the bioactive CCK8 peptide is able to enhance the doxorubicin uptake into the carcinoma cells in vitro. The cytotoxicity effect of liposomal doxorubicin on A431 cells has been assessed by MTT assays: in presence of drug amounts ranged between 250 and 1000 ng/ml, incubation with peptide derivatized liposomes showed significantly lower cell survival compared with nontargeted liposomes.

UR - http://www.scopus.com/inward/record.url?scp=79954509792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954509792&partnerID=8YFLogxK

U2 - 10.1002/bip.21491

DO - 10.1002/bip.21491

M3 - Article

C2 - 20560147

AN - SCOPUS:79954509792

VL - 96

SP - 88

EP - 96

JO - Biopolymers

JF - Biopolymers

SN - 0006-3525

IS - 1

ER -